Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US

http://www.therapeuticsdaily.com/news/article.cfm?contentvalue=627468&contenttype=newsarchive&channelID=26

Comments are closed.